Immupharma (IMM)

 

IMM Share PerformanceMore

52 week high104.28 13/11/17
52 week low35.50 21/11/16
52 week change 61.25 (166.67%)
4 week volume6,837,738 24/10/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Lupuzor trial on track, says ImmuPharma

ImmuPharma is on track to report top line results from its 52-week, randomised, double-blinded, phase III clinical trial of ...

Update on LupuzorT Pivotal Phase III Study

RNS Number: 3263V Immupharma PLC 02 November 2017 2 November 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to provide an update of its pivotal 52-week, randomised, double-blinded, Phase III clinic...

Holding(s) in Company

RNS Number: 7306T Immupharma PLC 16 October 2017 TR-1: S tandard form for notification of major holdings 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Immupharma Plc 213800VZKGHXC7VUS895 1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK iss...

ImmuPharma completes sharing agreement with Lanstead

ImmuPharma has announced the completion of the sharing agreement entered into with Lanstead Capital in February 20...

Completion of Lanstead Sharing Agreement

RNS Number: 6150S Immupharma PLC 04 October 2017 4 OCTOBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") Completion of Lanstead Sharing Agreement ImmuPharma plc (LSE: IMM), the specialist drug discovery and development company , wishes to announce the completion of the Sharing Agreement entered into with Lanstead Capital L....

ImmuPharma revenues rise

ImmuPharma's operating losses narrowed slightly in the six months to end of June falling to 3,186,951 from 3,239,547. Reven...

Interim Results

RNS Number: 8856R Immupharma PLC 27 September 2017 FOR IMMEDIATE RELEASE 27 SEPTEMBER 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2017 ImmuPharma PLC (LSE:IMM) , ("ImmuPharma" or the "Company"), the specialist drug discovery and develo...

Preparation of Lupuzor'sT Regulatory Submissions

RNS Number: 7616R Immupharma PLC 26 September 2017 RNS: FOR IMMEDIATE RELEASE 26 September 2017 ImmuPharma PLC ("ImmuPharma" or the "Company") ImmuPharma initiates preparation of Lupuzor's regulatory submissions ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to confirm a furthe...

Fundamental DataMore

EPS-4.54
Dividend yield0 %

Latest discussion posts More

  • Re: 100p now.. wow

    I've stopped selling now Chrissp.. but that's perhaps 'for now' instead of 'now' though.. I'd think about selling a little more at 115p if it were to go there.. obviously if in ...
    18-Oct-2017
    Nice to Michu
  • Re: 9.5% rise...

    That was a lucky top up over 100% gain @ #1 / :-)
    9-Oct-2017
    Ripley94
  • Re: 100p now.. wow

    Nice to Michu - interesting that you have sold some of your holding. I am keeping all mine that I have accumulated over many years at an average of 62P. This is the first time ...
    9-Oct-2017
    Chrissp

Users' HoldingsMore

Users who hold Immupharma also hold..
LLOYDS GRP.26%
BP18%
SIRIUS MINERALS18%
BARCLAYS13%
BT GROUP13%

Codes & Symbols

ISINGB0033711010
SymbolsIMM, LSE:IMM, IMM.L, IMM:LN, LON:IMM, XLON:IMM

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account